EUVIMEDEUVIMED entdecken
LeserbriefRandomisierte kontrollierte Studie

Response by Henriksen et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”

Peter A Henriksen iD, Peter Hall iD, Ninian N Lang iD

Circulation · 2024

DOI: 10.1161/circulationaha.124.069375 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Circulation, 2024. Verfasst von Peter A Henriksen und 2 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Centre for Cardiovascular Science (P.A.H.), University of Edinburgh, UK. Hauptthemen laut MEDLINE: Troponin I, Cardiotoxicity, Anthracyclines, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Troponin ICardiotoxicityAnthracyclinesAdrenergic beta-AntagonistsHumansAngiotensin Receptor AntagonistsRandomized Controlled Trials as TopicProspective StudiesMulticenter Studies as TopicDrug Therapy, Combination

Substanzen

Troponin IAnthracyclinesAdrenergic beta-AntagonistsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • British Heart Foundation Centre for Cardiovascular Science (P.A.H.), University of Edinburgh, UK.
  • Cancer Research UK - Edinburgh Centre (P.H.), University of Edinburgh, UK.
  • Medical Research Council Institute Genetics and Molecular Medicine (P.H.), University of Edinburgh, UK.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, UK (N.N.L.).

ORCID-Profile: Peter A Henriksen, Peter Hall, Ninian N Lang

Zitieren

APA

Henriksen, P. A., Hall, P., & Lang, N. N. (2024). Response by Henriksen et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”. Circulation. https://doi.org/10.1161/circulationaha.124.069375

Vancouver

Henriksen PA, Hall P, Lang NN. Response by Henriksen et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”. Circulation. 2024. doi:10.1161/circulationaha.124.069375

BibTeX
@article{Henriksen2024,
  author = {Henriksen, Peter A and Hall, Peter and Lang, Ninian N},
  title = {Response by Henriksen et al Regarding Article, “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial”},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.124.069375}
}
Kostenlos starten →